華領醫藥(02552.HK)考慮研究其藥物對染新冠病毒糖尿病人作用
華領醫藥(02552.HK)早前公佈,其糖尿病藥多格列艾汀(dorzagliatin)的一項研究顯示,使用者在停用該藥後52周,糖尿病緩解率爲65.2%。集團創始人、首席執行官、首席科學官陳力表示,結果顯示,病人身體在停藥後身體向好發展,糖尿病情並無惡化。他認爲,糖尿病人可能更容易感染新型冠狀病毒,感染之後很有可能引起重症,指該公司研發的藥物是否能夠緩解這類病人病情,是研究的考慮範圍之內。
陳力說,目前集團和數間公司合作,包括德國醫廠拜耳,他們提供資金首付等支持,有助支撐集團產品開發,目前希望利用自身資金擴展業務。他指,拜耳在中國有非常好的醫生和專家網絡,他們今年在業界組織了數場討論會介紹多格列艾汀的作用和研究結果,同時正積極準備銷售團隊,以便藥物上市後全速進入市場,集團內部也建立商務團隊,合作方國藥集團也會合作管理物流。
陳力說,國家採取藥品集中採購,是爲了讓更多糖尿病患者能夠使用胰島素,認爲該藥屬於剛性需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.